Related Experiment Video
Updated: Jul 13, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin
Hirokazu Kawano1, Shintaro Komaba, Tsugiko Yamasaki
1Saito Institute for Drug Discovery, Research and Development, Genomidea Inc., Ibaraki, Osaka, Japan.
Purpose:
To establish a new therapeutic method to treat bladder carcinoma, we investigated the therapeutic potential of doxorubicin hydrochloride (DXR) combined with hemagglutinating virus of Japan-envelope vector (HVJ-E) in an orthotropic mouse bladder cancer model.
Methods:
DXR and/or HVJ-E were instilled into the bladder after implantation of MB49 cells. Antitumor effects of combination therapy were evaluated by histological analysis of the bladder on day 14 after tumor implantation. The survival rate of MB49-disseminated mice was examined for 60 days after single or double administration of DXR alone or DXR/HVJ-E. The surviving mice were re-challenged with intravesical injection of MB49 cells, and the bladder was observed after 3 weeks.
Results:
Combined intravesical instillation of HVJ-E and DXR resulted in a significantly higher rate of tumor-free mice (11/21) compared with mice treated using DXR alone (3/19, P<0.05). Median survival was >60 days for intravesical instillation of HVJ-E and DXR, compared with the 29 days for DXR instillation alone (P<0.05). After combination therapy, surviving mice formed no tumors in the bladder following intravesical re-instillation of MB49.
Conclusions:
HVJ-E increased antitumor effects in combination with chemotherapeutic agent (DXR). Antitumor immunity appeared to be enhanced using HVJ-E.
Insights
Combining hemagglutinating virus of Japan-envelope vector (HVJ-E) with doxorubicin hydrochloride (DXR) offers a promising new bladder cancer therapy. This combination significantly improved tumor eradication and survival rates in mice, suggesting enhanced antitumor immunity.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Bladder carcinoma presents a significant therapeutic challenge.
- Doxorubicin hydrochloride (DXR) is a conventional chemotherapeutic agent.
- Hemagglutinating virus of Japan-envelope vector (HVJ-E) has potential as a drug delivery vector.
Purpose of the Study:
- To evaluate the therapeutic efficacy of combining DXR with HVJ-E for bladder cancer.
- To establish a novel treatment strategy for bladder carcinoma using a combination therapy.
Main Methods:
- An orthotropic mouse bladder cancer model (MB49 cells) was utilized.
- Intravesical instillation of DXR and/or HVJ-E was performed.
- Antitumor effects were assessed via histological analysis, survival rates, and tumor re-challenge experiments.
Main Results:
- Combination therapy with intravesical HVJ-E and DXR significantly increased the rate of tumor-free mice compared to DXR alone (11/21 vs. 3/19).
- Median survival was significantly extended in the combination therapy group (>60 days) versus DXR alone (29 days).
- Surviving mice receiving combination therapy demonstrated complete resistance to subsequent MB49 tumor re-implantation, indicating induced antitumor immunity.
Conclusions:
- HVJ-E enhances the antitumor effects of DXR in bladder cancer treatment.
- The combination therapy appears to stimulate antitumor immunity, offering a potential new therapeutic avenue.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers